Concord Biotech Limited (CONCORDBIO:NSE) Annual Income Statement ()
CONCORDBIO:NSE Quarterly Financials ()
Frequently Asked Questions About Concord Biotech Limited (CONCORDBIO:NSE) Stock
Concord Biotech Limited's (CONCORDBIO:NSE) last reported annual revenue was INR 9.98 Billion.
Concord Biotech Limited's (CONCORDBIO:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Concord Biotech Limited's(CONCORDBIO:NSE) is profitable as of its last reported annual financials.
The net profit margin for Concord Biotech Limited's(CONCORDBIO:NSE) from its laster reported year is 30.87%
The return on equity (ROE) for Concord Biotech Limited's(CONCORDBIO:NSE) from its last reported annual financials is : 22.27%
The return on assets (ROA) for Concord Biotech Limited's(CONCORDBIO:NSE) from its last reported annual financials is : 15.58%
The return on invested capital (ROIC) for Concord Biotech Limited's(CONCORDBIO:NSE) from its last reported annual financials is : 37.05%
The Debt to Equity ratio for Concord Biotech Limited's(CONCORDBIO:NSE) from its last reported annual financials is : 0.00%
The dividend yield for Concord Biotech Limited's(CONCORDBIO:NSE) from its laster reported year is 0.41%
Concord Biotech Limited's(CONCORDBIO:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CONCORDBIO:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
